Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways

Blood (2012) 120 (12): 2529–2536.

https://doi.org/10.1182/blood-2012-06-438911

Published: 2012

Journal Articles

The Efficacy and Safety of VP-16 and G-CSF as a Mobilization Regimen Prior to Autologous Stem Cell Transplantation (ASCT) for Patients (Pts) with Multiple Myeloma (MM) and Lymphoma.

William A. Wood, MD, MPH, Julia Whitley, Dominic T Moore, PhD, Jonathan S Serody, MD, Don A. Gabriel, MD, PhD, James M. Coghill, MD, Robert Irons, PA-C, Thomas C. Shea, MD

Blood (2009) 114 (22): 4225.

https://doi.org/10.1182/blood.V114.22.4225.4225

Published: 2009

Journal Articles

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Thomas Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Anastasia Ivanova, PhD, Dominic Moore, PhD, Robert Irons, PA, Whitley Julia, BS, Sharf Andrew, RN, Cherie Dunphy, MD, Brecher Mark, MD

Blood (2007) 110 (11): 4940.

https://doi.org/10.1182/blood.V110.11.4940.4940

Published: 2007

Journal Articles

Symptomatic Improvement Following Intravesicular Cidofovir for the Management of BK Virus Associated Cystitis.

Larry W. Buie, PharmD, Kamakshi V. Rao, PharmD, Stacy Epstein, PharmD, Thomas C. Shea, MD, Terrence Comeau, MD, Don A. Gabriel, MD PhD, Robert Irons, PA, Barbara Eron, RN, Jonathan Serody, MD PhD

Blood (2007) 110 (11): 3007.

https://doi.org/10.1182/blood.V110.11.3007.3007

Published: 2007

Journal Articles

Clinical and Pharmacokinetic Results of a Four-Day Continuous Infusion of Full-Dose Busulfan in Patients (pts) Undergoing Matched Related (MRD) or Unrelated (MUD) Stem Cell Transplant (SCT).

Thomas C. Shea, MD, Christine Walko, PharmD, Don Gabriel, MD, PhD, Jon Serody, MD, PhD, Terrance Comeau, MD, Robert Irons, PA, Andrew Gilman, MD, Carol Krasnov, Andrew Sharf, RN, Celeste Lindley, PharmD

Blood (2005) 106 (11): 1752.

https://doi.org/10.1182/blood.V106.11.1752.1752

Published: 2005

Journal Articles

Long Term Effects on GVHD and Survival Following the Use of G-CSF Stimulated Bone Marrow Versus G-CSF Mobilized Peripheral Blood Stem Cells in HLA Matched Sibling Transplant.

Anne W. Beaven, MD, Thomas C. Shea, MD, Don A. Gabriel, MD, PhD, Terrance Comeau, MD, Robert Irons, PA, Dominic T. Moore, MS, MPH, Li Lin, MS, Andrew Sharf, RN, Carol Krasnov, Mark E. Brecher, MD, Jonathan Serody, MD, PhD

Blood (2005) 106 (11): 5385.

https://doi.org/10.1182/blood.V106.11.5385.5385

Published: 2005

Journal Articles

High Relapse Rate Following Alemtuzamab Use in Allogeneic Transplants for Myeloid Hematologic Malignancies.

Thomas C. Shea, MD, Jonathan Serody, MD, PhD, Don Gabriel, MD, PhD, Terrance Comeau, MD, Donald Harvey, PharmD, Robert Irons, PA, David Morris, MD, Andrew Sharf, RN, Carol Krasnov, Cherie Dunphy, MD, Nicholas Banderenko, MD, Mark Brecher, MD

Blood (2004) 104 (11): 1826.

https://doi.org/10.1182/blood.V104.11.1826.1826

Published: 2004

Journal Articles

Successful Re-Engraftment after Second Allogeneic Transplantation for Graft Failure in Patients with Refractory Hematologic Malignancies.

Don A. Gabriel, MD, PhD, James Coghill, MD, Thomas C. Shea, MD, Terrance Comeau, MD, Robert Irons, P-AC, Carol Krasnov

Blood (2004) 104 (11): 5120.

https://doi.org/10.1182/blood.V104.11.5120.5120

Published: 2004

NARROW

B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways

The Efficacy and Safety of VP-16 and G-CSF as a Mobilization Regimen Prior to Autologous Stem Cell Transplantation (ASCT) for Patients (Pts) with Multiple Myeloma (MM) and Lymphoma.

Low Incidence of GVHD and Treatment-Related Morbidity (TRM) with Intermediate Doses of Continuous Infusion IV Busulfan and Daily Fludarabine with Individualized Doses of Alemtuzamab for Matched Related (MRD) and Unrelated (MUD) Transplant Pts with High-Risk Hematologic Malignancies.

Symptomatic Improvement Following Intravesicular Cidofovir for the Management of BK Virus Associated Cystitis.

Clinical and Pharmacokinetic Results of a Four-Day Continuous Infusion of Full-Dose Busulfan in Patients (pts) Undergoing Matched Related (MRD) or Unrelated (MUD) Stem Cell Transplant (SCT).

Long Term Effects on GVHD and Survival Following the Use of G-CSF Stimulated Bone Marrow Versus G-CSF Mobilized Peripheral Blood Stem Cells in HLA Matched Sibling Transplant.

High Relapse Rate Following Alemtuzamab Use in Allogeneic Transplants for Myeloid Hematologic Malignancies.

Successful Re-Engraftment after Second Allogeneic Transplantation for Graft Failure in Patients with Refractory Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only